Press Release FeedGet the RSS feed
Menu

Business Wire

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Business Wire

LEXINGTON, Mass., October 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

The clinical poster will review the features of long-term survivors of refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) who have been treated with BOT+BAL. A second poster will highlight translational research of BOT+BAL in combination with MiNK Therapeutics' agenT-797 (iNKT cell therapy) with in a preclinical model of colorectal cancer liver metastases.

Presentation Details

Abstract Title: Clinical features of long-term survivors treated with next-generation anti-CTLA-4 (botensilimab) plus anti-PD-1 (balstilimab) in refractory microsatellite-stable metastatic colorectal cancer
Presenter: Anthony El-Khoueiry, MD.; USC Norris Comprehensive Cancer Center, Los Angeles, CA
Date: Saturday, November 7, 2026
Time: 10:00 a.m. - 2:00 p.m. and 6:00-8:10 p.m. MST
Location: North Building, Lower Level, Exhibition Halls 4–5–6
Poster No.: 472

Abstract Title: AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
Presenter: Shanmugarajan Krishnan, Ph.D., M.S., B.S.; Agenus Inc., Lexington, MA
Date: Saturday, November 7, 2026
Time: 10:00 a.m. to 2:00 p.m. and 6:00 to 8:10 p.m. MST
Location: North Building, Lower Level, Exhibition Halls 4–5–6
Poster No.: 270

About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

  1. EnergyWorld’s First Commercial Ship-to-Ship Green Ammonia Bunkering Completed in Zhoushan, Zhejiang, ChinaZHOUSHAN, China, October 18, 2026--On October 13, 2026, the world's first commercial ship-to-ship bunkering of green ammonia fuel was completed at an anchorage in Zhoushan Port, Zhejiang Province, China. A total of 1,000 tonnes of green ammonia from the HyFlow-1 Songyuan Hydrogen Energy Industrial Park
  2. SaaSThe Prostate Cancer FoundationProstate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types – – New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges i
  3. FinanceAlign Technology, Inc.Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent CourtCompanies: Align TechnologySAN JOSE, Calif. & TEMPE, Ariz., October 17, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court ("UPC") finding that aligner syst
  4. AISyncra and Neumetry Partner to Build AI-Powered Readiness Platform for Teenage Athletes and Their CoachesSmart ring data meets FDA-cleared physiological AI to help coaches see which athletes are ready to compete, and which need rest LAS VEGAS & SAN JOSE, Calif., October 17, 2026--Syncra Labs Inc., maker of the Syncra smart ring, and Neumetry Medical, Inc., developer of an FDA-cleared predictive health pla
  5. HealthcareAIDS Healthcare FoundationAHF Commemorates 40 Years of Global Impact During Annual World AIDS Day Concert Celebration Featuring Ricky MartinLOS ANGELES, October 16, 2026--AIDS Healthcare Foundation (AHF) , the world's largest, non-profit public health organization providing direct HIV/ADS services to over 3.3 million clients across the globe, will celebrate 40 years of impact during its annual World AIDS Day concert commemoration. Continu
  6. Real estateKBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6)NEW YORK, October 16, 2026--KBRA assigns preliminary ratings to ten classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6), a $250.6 million non-prime RMBS transaction. The underlying collateral, comprised of 381 residential mortgages, and includes a meaningful conce